TuisFGEN • NASDAQ
add
FibroGen Inc
Vorige sluiting
$8,42
Dagwisseling
$8,30 - $8,54
Jaarwisseling
$4,85 - $21,94
Markkapitalisasie
33,82 m USD
Gemiddelde volume
32,22 k
P/V-verhouding
0,16
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,08 m | 774,80% |
Bedryfskoste | 5,30 m | -43,44% |
Netto inkomste | 200,64 m | 1 274,41% |
Netto winsgrens | 18,65 k | 234,25% |
Wins per aandeel | 49,61 | 13 491,78% |
EBITDA | -5,18 m | 81,77% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 117,98 m | -9,94% |
Totale bates | 137,01 m | -48,18% |
Totale aanspreeklikheid | 119,53 m | -74,36% |
Totale ekwiteit | 17,48 m | — |
Uitstaande aandele | 4,05 m | — |
Prys om te bespreek | -2,00 | — |
Opbrengs op bates | -8,52% | — |
Opbrengs op kapitaal | 52,71% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 200,64 m | 1 274,41% |
Kontant van bedrywe | -1,85 m | 77,95% |
Kontant van beleggings | 87,16 m | 11 444,37% |
Kontant van finansiering | -85,92 m | -67 551,18% |
Netto kontantverandering | -1,87 m | 80,78% |
Beskikbare kontantvloei | 72,84 m | 1 077,84% |
Meer oor
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2025, FibroGen was mainly reduced to a single early-stage oncology drug candidate. Wikipedia
Gestig
01 Jan. 1993
Webwerf
Werknemers
225
